Astrana Health (NASDAQ:ASTH) Price Target Raised to $86.00

Astrana Health (NASDAQ:ASTH) had its target price upped by Robert W. Baird from $67.00 to $86.00 in a report published on Wednesday morning,Benzinga reports. They currently have an outperform rating on the stock.

Several other equities analysts have also recently weighed in on ASTH. KeyCorp started coverage on Astrana Health in a research note on Friday, October 11th. They issued a “sector weight” rating on the stock. BTIG Research upped their price target on shares of Astrana Health from $60.00 to $70.00 and gave the company a “buy” rating in a research report on Thursday, October 3rd. Stifel Nicolaus raised their price objective on shares of Astrana Health from $48.00 to $60.00 and gave the stock a “buy” rating in a report on Thursday, August 1st. TD Cowen began coverage on shares of Astrana Health in a report on Monday, October 14th. They set a “buy” rating and a $66.00 target price for the company. Finally, Truist Financial lifted their price target on shares of Astrana Health from $50.00 to $59.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Astrana Health has an average rating of “Buy” and a consensus price target of $65.17.

Astrana Health Price Performance

NASDAQ ASTH opened at $40.81 on Wednesday. Astrana Health has a one year low of $32.04 and a one year high of $63.20. The stock has a 50-day moving average of $55.04 and a 200 day moving average of $47.74. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.84 and a current ratio of 1.91. The company has a market capitalization of $2.30 billion, a price-to-earnings ratio of 31.39, a PEG ratio of 1.96 and a beta of 1.24.

Astrana Health (NASDAQ:ASTH) last announced its quarterly earnings results on Thursday, November 7th. The company reported $0.33 EPS for the quarter, hitting analysts’ consensus estimates of $0.33. The firm had revenue of $478.71 million during the quarter, compared to analyst estimates of $462.01 million. Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. During the same period in the previous year, the business posted $0.47 earnings per share. On average, sell-side analysts forecast that Astrana Health will post 1.16 EPS for the current year.

Institutional Trading of Astrana Health

Hedge funds and other institutional investors have recently modified their holdings of the company. Diamond Hill Capital Management Inc. purchased a new stake in shares of Astrana Health during the third quarter worth about $8,245,000. Amalgamated Bank purchased a new stake in Astrana Health during the 3rd quarter valued at approximately $713,000. Summit Global Investments bought a new position in shares of Astrana Health during the third quarter worth $753,000. Louisiana State Employees Retirement System purchased a new position in Astrana Health during the third quarter valued at $1,165,000. Finally, F M Investments LLC bought a new stake in Astrana Health in the 3rd quarter valued at $11,738,000. 52.77% of the stock is owned by hedge funds and other institutional investors.

About Astrana Health

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.